JMP Securities analyst Jason Butler raised the firm’s price target on Rezolute (RZLT) to $8 from $7 and keeps an Outperform rating on the shares following Q1 results. The Phase 3 trial for ersodetug in congenital hyperinsulinism continues to enroll patients and results remain on track for 2H25, the firm noted.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.